ISDA

Deposition Date 2018-12-05

Release Date 2019-12-11

Last Version Date 2024-11-20

Entry Detail

PDB ID:

6NAE

Keywords:

VIRAL PROTEIN

Title:

Crystal Structure of Ebola zaire GP protein with bound ARN0074898

Biological Source:

Source Organism:

Zaire ebolavirus (strain Mayinga-76) (Taxon ID: 128952)

Host Organism:

Homo sapiens

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.75 Å

R-Value Free:

0.23

R-Value Work:

0.19

R-Value Observed:

0.19

Space Group:

H 3 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Envelope glycoprotein,Envelope glycoprotein,Envelope glycoprotein
Gene (Uniprot):GP
Mutations:T42A
Chain IDs:A
Chain Length:330
Number of Molecules:1
Biological Source:Zaire ebolavirus (strain Mayinga-76)

UniProt ID:Q05320 Pfam ID:PF01611, PF22307

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Envelope glycoprotein
Gene (Uniprot):GP
Mutations:H613A
Chain IDs:B
Chain Length:168
Number of Molecules:1
Biological Source:Zaire ebolavirus (strain Mayinga-76)

UniProt ID:Q05320 Pfam ID:PF01611, PF22307

Ligand Molecules

GOL

KHG

NAG

Primary Citation

Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors.

Plewe, M.B, Sokolova, N.V, Gantla, V.R, Brown, E.R, Naik, S, Fetsko, A, Lorimer, D.D, Dranow, D.M, Smutney, H, Bullen, J, Sidhu, R, Master, A, Wang, J, Kallel, E.A, Zhang, L, Kalveram, B, Freiberg, A.N, Henkel, G, McCormack, K.Show

Acs Med.Chem.Lett. 11 1160 1167 (2020)

PMID: 32550996 DOI: 10.1021/acsmedchemlett.0c00025

Abstact

We identified and explored the structure-activity-relationship (SAR) of an adamantane carboxamide chemical series of Ebola virus (EBOV) inhibitors. Selected analogs exhibited half-maximal inhibitory concentrations (EC50 values) of ∼10-15 nM in vesicular stomatitis virus (VSV) pseudotyped EBOV (pEBOV) infectivity assays, low hundred nanomolar EC50 activity against wild type EBOV, aqueous solubility >20 mg/mL, and attractive metabolic stability in human and nonhuman liver microsomes. X-ray cocrystallographic characterizations of a lead compound with the EBOV glycoprotein (GP) established the EBOV GP as a target for direct compound inhibitory activity and further provided relevant structural models that may assist in identifying optimized therapeutic candidates.

Legend

Protein

Chemical

Disease

Primary Citation of related structures